GeoVax’s EMA guidance provides clear pathway, says Alliance Global Partners

Alliance Global Partners reiterates a Buy rating and $8.50 price target on shares of GeoVax Labs (GOVX), telling investors in a research note that the positive Scientific Advice from the European Medicines Agency regarding their GEO-MVA candidate vaccine for the prevention of Mpox and smallpox provides a clear regulatory pathway ahead, and if successful, could lead to a potential accelerated regulatory approval timeline. This feedback also comes as the World Health Organization issued its fourth declaration of Mpox as a Public Health Emergency of International Concern, further reiterating the need to create preventative measures for Mpox, the firm says.